Equine West Nile Viral Encephalomyelitis – NAVLE Study Guide

Overview and Clinical Importance

West Nile Virus (WNV) is a mosquito-borne flavivirus that causes neuroinvasive disease in horses and is the most common arboviral encephalitis in North America. First identified in the United States in 1999, WNV has become endemic throughout the continent. The virus is maintained in a bird-mosquito-bird transmission cycle, with horses and humans serving as incidental "dead-end" hosts. Understanding WNV is essential for NAVLE success as it represents a significant component of equine infectious neurological diseases.

Approximately 80% of infected horses remain asymptomatic, while 20% develop clinical disease. Of those showing clinical signs, the case fatality rate is approximately 33%, with an additional 10-20% recovering with residual neurologic deficits. The American Association of Equine Practitioners (AAEP) classifies WNV vaccination as a core vaccine for all horses in North America.

Etiology and Virology

West Nile virus is a single-stranded, positive-sense RNA virus belonging to the family Flaviviridae and genus Flavivirus. It is a member of the Japanese encephalitis serocomplex, which includes St. Louis encephalitis virus, Murray Valley encephalitis virus, and Japanese encephalitis virus. The virus is approximately 45-50 nm in diameter with an icosahedral envelope.

Virus Classification and Characteristics

Epidemiology and Transmission

Transmission Cycle

WNV is maintained in nature through an enzootic bird-mosquito-bird transmission cycle. Birds, particularly passerines (American robins, house sparrows) and corvids (crows, jays), serve as the primary amplifying reservoir hosts. These birds develop high levels of viremia sufficient to infect feeding mosquitoes. Mosquitoes of the genus Culex (especially C. pipiens, C. tarsalis, and C. quinquefasciatus) are the primary vectors.

Horses and humans are considered incidental or "dead-end" hosts because they develop insufficient viremia levels to infect feeding mosquitoes. This means infected horses cannot transmit WNV to other horses, humans, or mosquitoes. Consequently, there is no need for quarantine of WNV-infected horses.

WNV Transmission Cycle Components

Seasonality and Geographic Distribution

WNV transmission occurs primarily during late summer and early fall (July-October) in temperate climates when mosquito populations peak. In warmer climates with year-round mosquito activity, transmission may occur throughout the year. The virus is now endemic throughout all 48 contiguous United States, Canada, Mexico, and parts of Central and South America.

Pathogenesis

Following inoculation by an infected mosquito bite, WNV replicates initially in local dendritic cells and migrates to regional lymph nodes. Viremia develops within 1-3 days post-infection, though levels remain low in horses (100-1000 PFU/mL). The incubation period ranges from 3-15 days. Neuroinvasion occurs through hematogenous spread across the blood-brain barrier, direct axonal transport via peripheral nerves, or infection of olfactory neurons.

Within the CNS, WNV demonstrates tropism for neurons, particularly in the gray matter of the brainstem, thalamus, and spinal cord ventral horns. The resulting pathology is a nonsuppurative polioencephalomyelitis characterized by perivascular lymphocytic cuffing, microglial nodules, neuronal degeneration, and gliosis. Notably, WNV antigen is often scant within lesions, indicating that immune-mediated damage contributes significantly to pathology.

WNV Pathogenesis Timeline

Clinical Signs

The clinical presentation of WNV encephalomyelitis is highly variable and can mimic other neurological diseases. The onset of neurologic signs is often sudden and progressive. All age horses are susceptible, though older horses and unvaccinated horses tend to develop more severe disease.

Hallmark Clinical Features

The major hallmarks of equine WNV encephalomyelitis are:

• Muscle fasciculations - especially of the muzzle, face, and eyelids (often enhanced by light/photophobic)
• Personality/behavior changes - depression, anxiety, altered mentation
• Ataxia with hindlimb weakness - often asymmetric; may progress to recumbency

Clinical Signs by System

Diagnosis

Diagnosis of WNV requires integration of clinical signs, history (seasonality, vaccination status, geographic location), and laboratory testing. A presumptive diagnosis can be made based on compatible clinical signs during mosquito season, but laboratory confirmation is essential because WNV resembles other reportable diseases (rabies, EEE).

Laboratory Diagnosis

Serology - Test of Choice

The IgM capture ELISA (MAC-ELISA) is the test of choice for diagnosing acute WNV infection in horses. IgM antibodies are short-lived, indicating recent infection. A positive IgM titer greater than or equal to 1:400 in serum or CSF of a horse with compatible clinical signs confirms diagnosis. IgM is typically detectable within 6 days post-infection and may persist for up to 2 months.

Diagnostic Testing Summary

CSF Analysis

CSF analysis is often normal or nonspecific in WNV cases. When abnormalities are present, findings may include mild to moderate pleocytosis (lymphocytic or mixed) and mildly elevated protein. A positive CSF IgM ELISA is highly supportive of CNS WNV infection since IgM does not cross an intact blood-brain barrier. CSF should be evaluated immediately for cytology or submitted promptly.

Histopathology

Postmortem histopathology reveals a characteristic nonsuppurative polioencephalomyelitis with perivascular lymphocytic cuffing, microglial nodules, gliosis, and neuronal degeneration. Lesions are most prominent in the thalamus, basal ganglia, midbrain, hindbrain (pons, medulla), and ventral horns of the spinal cord (especially thoracolumbar segments). Perivascular hemorrhages may be observed in approximately 50% of cases. Viral antigen is typically scant.

Differential Diagnosis

The clinical presentation of WNV overlaps significantly with other causes of equine neurological disease. A systematic approach to rule out differentials is essential, particularly for reportable diseases (rabies, EEE).

Exam Focus: All horses with acute neurologic signs during mosquito season should be treated as potential rabies suspects until proven otherwise. Handle with caution and submit brain for rabies testing (FA test) if the horse dies or is euthanized.

Treatment

There is no specific antiviral treatment for WNV infection. Management is supportive and symptomatic, aimed at controlling inflammation, managing secondary complications, and providing nursing care until the horse can mount an adequate immune response.

Treatment Protocols

Prognosis

Prognosis depends heavily on disease severity. Horses that remain standing have survival rates of 80-90%. Recumbent horses have a much poorer prognosis. Overall case fatality rate for clinically affected horses is approximately 33%. Up to 40% of survivors may have residual neurologic deficits (gait abnormalities, behavior changes) persisting 6 months or longer. Horses that survive and recover typically develop long-term immunity.

Prevention

Vaccination

WNV vaccination is classified as a CORE vaccine by the American Association of Equine Practitioners (AAEP), meaning it is essential for ALL horses in North America regardless of use or location. Four USDA-licensed vaccines are currently available.

USDA-Licensed WNV Vaccines

AAEP Vaccination Guidelines

Adult Horses (previously unvaccinated):

• Primary series of 2 doses, 3-6 weeks apart
• Annual booster prior to mosquito season (spring)
• More frequent boosters (semi-annual) in high-risk areas or year-round mosquito regions

Foals of Vaccinated Mares:

• 3-dose primary series beginning at 4-6 months of age
• 4-6 weeks between first and second doses
• Third dose at 10-12 months prior to mosquito season

Foals of Unvaccinated Mares:

• 3-dose primary series beginning at 3-4 months of age
• 30-day interval between first and second dose; 60-day interval between second and third dose

Mosquito Control and Environmental Management

• Eliminate standing water - clean water troughs weekly; remove tires, buckets, flower pots
• Reduce mosquito exposure - stable horses at dawn/dusk when Culex mosquitoes are most active
• Use fans in barns - disrupts mosquito flight
• Apply insect repellents - products containing DEET, permethrin, or pyrethrins
• Maintain screens - on barn windows and doors